1 December 2004 in Cancer Research
Tumor necrosis factor (TNF) family ligand TNF-α and Fas ligand (FasL) can trigger apoptosis in solid tumors, but their clinical usage has been limited by hepatotoxicity. TNF-related apoptosis-inducing ligand (TRAIL) is a newly identified member of the TNF family, and its clinical application currently is under a similar debate. Here, we report a recombinant soluble form of human TRAIL (114 to 281 amino acids) that induces apoptosis in tumor cells but not human hepatocytes. We first isolated human hepatocytes from patients and showed that the human hepatocytes expressed Fas but no TRAIL death receptor DR4 and little DR5 on the cell surface. Antibody cross-linked FasL, but not TRAIL, triggered apoptosis of the human hepatocytes through cleavage of caspases. We then examined TRAIL hepatotoxicity in severe combined immunodeficient/Alb-uPA chimeric mice harboring human hepatocytes. Intravenous injection of FasL, but not TRAIL, caused apoptotic death of human hepatocytes within the chimeric liver, thus killing the mice. Finally, we showed that repeated intraperitoneal injections of TRAIL inhibited intraperitoneal and subcutaneous tumor growth without inducing apoptosis in human hepatocytes in these chimeric mice. The results indicate that the recombinant soluble human TRAIL has a profound apoptotic effect on tumor cells but is nontoxic to human hepatocytes in vitro and in vivo.
1 February 2012 in Cancer Discovery
The TNF-related apoptosis-inducing ligand (TRAIL) apoptotic pathway has emerged as a therapeutic target for the treatment of cancer. However, clinical trials have proven that the vast majority of human cancers are resistant to TRAIL apoptotic pathway-targeted therapies. We show that A20-mediated ubiquitination inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma through 2 signaling complexes. A20 is highly expressed in glioblastomas and, together with the death receptor 5 and receptor-interacting protein 1, forms a plasma membrane-bound preligand assembly complex under physiologic conditions. Treatment with TRAIL leads to the recruitment of caspase-8 to the plasma membrane-bound preligand assembly complex for the assembly of a death-inducing signaling complex. In the death-inducing signaling complex, the C-terminal zinc finger (Znf) domain of the A20 ubiquitin ligase mediates receptor-interacting protein 1 polyubiquitination through lysine-63-linked polyubiquitin chains, which bind to the caspase-8 protease domain and inhibit caspase-8 dimerization, cleavage, and the initiation of TRAIL-induced apoptosis in glioblastoma-derived cell lines and tumor-initiating cells. Significance: These results identify A20 E3 ligase as a therapeutic target whose inhibition can overcome TNF-related apoptosis-inducing ligand resistance in glioblastoma and thus have an impact on ongoing clinical trials of TNF-related apoptosis-inducing ligand-targeted combination cancer therapies. Cancer Discovery; 2(2); 140–55. © 2012 AACR. Read the Commentary on this article by Verbrugge and Johnstone, p. 112. This article is highlighted in the In This Issue feature, p. 95.
22 March 2006 in Journal of Neuroscience
Human astrocytes express Fas yet are resistant to Fas-induced apoptosis. Here, we report that calcium/calmodulin-dependent protein kinase II (CaMKII) is constitutively activated in human astrocytes and protects the cells from apoptotic stimulation by Fas agonist. Once stimulated, Fas recruits Fas-associated death domain and caspase-8 for the assembly of the death-inducing signaling complex (DISC); however, caspase-8 cleavage is inhibited in the DISC. Inhibition of CaMKII kinase activity inhibits the expression of phosphoprotein enriched astrocytes-15 kDa/phosphoprotein enriched in diabetes (PEA-15/PED) and cellular Fas-associated death domain-like interleukin-1β-converting enzyme-inhibitory protein (c-FLIP), thus releasing their inhibition of caspase-8 cleavage. Inhibition of PEA-15/PED or c-FLIP by small interfering RNA sensitizes human astrocytes to Fas-induced apoptosis. In contrast, inhibition of CaMKII, PEA-15, or c-FLIP does not affect the sensitivity of human astrocytes to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). TRAIL death receptors (DR4, DR5) are weakly expressed at mRNA, protein, and cell surface levels and thus fail to mediate the assembly of the DISC in human astrocytes. Overexpression of DR5 restores TRAIL signaling pathways and sensitizes the human astrocytes to TRAIL-induced apoptosis if CaMKII kinase activity or expression of PEA-15 and c-FLIP is inhibited; the results suggest that CaMKII-mediated pathways prevent TRAIL-induced apoptosis in human astrocytes under conditions in which TRAIL death receptors are upregulated. This study has therefore identified the molecular mechanisms that protect normal human astrocytes from apoptosis induced by Fas ligand and TRAIL.
1 June 2010 in Journal of Cellular and Molecular Medicine
To explore the molecular mechanisms by which glioblastomas are resistant to tumour necrosis factor‐related apoptosis‐inducing ligand (TRAIL), we examined TRAIL signalling pathways in the tumours. TRAIL has four membrane‐anchored receptors, death receptor 4/5 (DR4/5) and decoy receptor 1/2 (DcR1/2). Of these receptors, only DR5 was expressed consistently in glioblastoma cell lines and tumour tissues, ruling out the role of DcR1/2 in TRAIL resistance. Upon TRAIL binding, DR5 was homotrimerized and recruited Fas‐associated death domain (FADD) and caspase‐8 for the assembly of death‐inducing signalling complex (DISC) in the lipid rafts of the plasma membrane. In the DISC, caspase‐8 was cleaved and initiated apoptosis by cleaving downstream caspases in TRAIL‐sensitive glioblastoma cells. In TRAIL‐resistant cells, however, DR5‐mediated DISC was modified by receptor‐interacting protein (RIP), cellular FADD‐like interleukin‐1β‐converting enzyme inhibitory protein (c‐FLIP) and phosphoprotein enriched in diabetes or in astrocyte‐15 (PED/PEA‐15). This DISC modification occurred in the non‐raft fractions of the plasma membrane and resulted in the inhibition of caspase‐8 cleavage and activation of nuclear factor‐κB (NF‐κB). Treatment of resistant cells with parthenolide, an inhibitor of inhibitor of κB (I‐κB), eliminated TRAIL‐induced NF‐κB activity but not TRAIL resistance. In contrast, however, targeting of RIP, c‐FLIP or PED/PEA‐15 with small interfering RNA (siRNA) led to the redistribution of the DISC from non‐rafts to lipid rafts and eliminated the inhibition of caspase‐8 cleavage and thereby TRAIL resistance. Taken together, this study indicates that the DISC modification by RIP, c‐FLIP and PED/PEA‐15 is the most upstream event in TRAIL resistance in glioblastomas.
14 February 2012 in Cancer Letters
30 August 2011 in Apoptosis